GSK bags EU approval for Blenrep
Blenrep is a first-line inhibitor of BCMA, a cell-surface protein that plays a crucial role in the survival of plasma cells and is expressed on multiple myeloma cells
Read More
Tag: BCMA
‘Breakthrough’ tag for GSK’s multiple myeloma drug
An investigational antibody-drug conjugate being developed by GlaxoSmithKline for patients with multiple myeloma has been awarded Breakthrough Therapy Designation from the US Food and Drug Administration.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
